CRA was retained by the claimant in an arbitration dispute concerning the alleged breach of a non-compete clause in an agreement to distribute a prescription women’s health product in a country in Asia. A CRA life sciences expert provided an expert report regarding the quantum of lost profits suffered by the claimant because of the alleged breach. In computing the estimate of quantum, the CRA Life Sciences team analyzed and addressed questions regarding the timing of market entry and product sales absent the alleged breach as well as the incremental profit per unit sold.
Looking ahead to 2026: Trends and expectations for International Arbitration
Across both investor-state and commercial cases, quantum debates have recently turned on attribution under concurrent shocks, the interaction of contract terms...